References Search
All References with Titles containing 'metachlorophenylpiperazine OR mcpp OR mchlorophenylpiperazine' OR with Authors including 'metachlorophenylpiperazine OR mcpp OR mchlorophenylpiperazine' OR with Abstract including 'metachlorophenylpiperazine OR mcpp OR mchlorophenylpiperazine' OR with Keywords including 'metachlorophenylpiperazine OR mcpp OR mchlorophenylpiperazine'
| Author |
Title |
JournalName |
Year D |
| Click on Column Headers to Re-Sort The Current List |
| Samanin R, Mennini T, Fer... |
m-Chlorophenylpiperazine: A Central Serotonin Agonist Causing Powerful... |
Naunyn-Schmiedeberg'... |
1979 |
| Aloi JA, Insel TR, Muelle... |
Neuroendocrine and Behavioral Effects of m-Chlorophenylpiperazine Admi... |
Life Sciences |
1984 |
| McKenney JD, Glennon RA |
TFMPP May Produce its Stimulus Effects Via a 5-HT1B Mechanism |
Pharmacology Biochem... |
1986 |
| Charney DS, Woods SW, Goo... |
Serotonin function in anxiety II. Effects of the serotonin agonist MCP... |
Psychopharmacology B... |
1987 |
| Charney DS, Goodman WK, P... |
Serotonin function in obsessive-compulsive disorder A comparison of th... |
Arch Gen Psychiatry |
1988 |
| Schechter MD |
Use of TFMPP stimulus properties as a model of 5-HT1B receptor activat... |
Pharmacol Biochem Be... |
1988 |
| Kahn RS, Wetzler S, Asnis... |
Effects of m-chlorophenylpiperazine in normal subjects: a dose-respons... |
Psychopharmacology (... |
1990 |
| Frambes NA, Kirstein CL, ... |
5-HT1A, 5-HT1B and 5-HT2 receptor agonists induce differential behavio... |
Eur J Pharmacol |
1990 |
| Chaouloff F, Laude D, Bau... |
Effects of the 5-HT1C/5-5-HT2 receptor agonists DOI and alpha-methyl-5... |
Eur J Pharmacol |
1990 |
| Boja JW, Schechter MD |
Possible serotonergic and dopaminergic mediation of the N-ethyl-3,4-me... |
Eur J Pharmacol |
1991 |
| Chaouloff F, Baudrie V, L... |
The 5-HT2 receptor agonist 1-2,5-dimethoxy-4-iodophenyl2-aminopropane ... |
Eur J Pharmacol |
1992 |
| Chaouche-Teyara K, Fourni... |
Vascular and cardiac effects of alpha-methyl-5-HT and DOI are mediated... |
Eur J Pharmacol |
1993 |
| Rotzinger S, Fang J, Bake... |
Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from hu... |
Drug Metab Dispos |
1998 |
| Leone M, Attanasio A, Cro... |
The serotonergic agent m-chlorophenylpiperazine induces migraine attac... |
Neurology |
2000 |
| Baumann MH, Ayestas MA, D... |
1-(m-chlorophenyl)piperazine (mCPP) dissociates in vivo serotonin rele... |
Neuropsychopharmacol... |
2001 |
| Tancer, ME, Johanson, C-E |
The subjective effects of MDMA and mCPP in moderate MDMA users |
Drug and Alcohol Dep... |
2001 |
| Rothman R, Baumann M |
Therapeutic and adverse actions of serotonin transporter substrates |
Pharmacol Ther |
2002 |
| Gobbi M, Moia M, Pirona L... |
p-Methylthioamphetamine and 1-(m-chlorophenyl)piperazine, two non-neur... |
J Neurochem |
2002 |
| Taffe MA, Davis SA, Yuan ... |
Cognitive performance of MDMA-treated rhesus monkeys: sensitivity to s... |
Neuropsychopharmacol... |
2002 |
| Peters FT, Schaefer S, St... |
Screening for and validated quantification of amphetamines and of amph... |
J Mass Spectrom |
2003 |
| Taffe MA, Huitron-Resendi... |
MDMA exposure alters cognitive and electrophysiological sensitivity to... |
Pharmacol Biochem Be... |
2003 |
| Tancer M, Johanson CE |
Reinforcing, subjective, and physiological effects of MDMA in humans: ... |
Drug Alcohol Depend |
2003 |
| Maurer HH, Kraemer T, Spr... |
Chemistry, pharmacology, toxicology, and hepatic metabolism of designe... |
Ther Drug Monit |
2004 |
| Feuchtl A, Bagli M, Steph... |
Pharmacokinetics of m-chlorophenylpiperazine after intravenous and ora... |
Pharmacopsychiatry |
2004 |
| Staack RF, Maurer HH |
Metabolism of designer drugs of abuse |
Curr Drug Metab |
2005 |
| Bossong MG, Van Dijk JP, ... |
Methylone and mCPP, two new drugs of abuse? |
Addict Biol |
2005 |
| Johanson CE, Kilbey M, Ga... |
Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine (... |
Drug Alcohol Depend |
2006 |
| Vogels N, Brunt TM, Rigte... |
Content of ecstasy in the Netherlands: 1993-2008 |
Addiction |
2009 |
| Bossong MG, Brunt TM, Van... |
mCPP: an undesired addition to the ecstasy market |
J Psychopharmacol |
2010 |
| Brunt TM, Koeter MW, Nies... |
Linking the pharmacological content of ecstasy tablets to the subjecti... |
Psychopharmacology (... |
2011 |
| Arbo MD, Bastos ML, Carmo... |
Piperazine compounds as drugs of abuse |
Drug Alcohol Depend |
2011 |
| Castelli R2, Thornton SL,... |
True or False? Analysis of phencyclidine positive urine drug immunoass... |
NAACT Abstract |
2015 |
| Adamowicz P, Gieron J, Gi... |
The prevalence of new psychoactive substances in biological material -... |
Drug Test Anal |
2015 |
| Odoardi S, Romolo FS, Str... |
A snapshot on NPS in Italy: Distribution of drugs in seized materials ... |
Forensic Sci Int |
2016 |
